Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Overview | 9 | 1 |
| Therapeutics Development | 10 | 4 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Products under Development by Stage of Development | 10 | 1 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Products under Development by Therapy Area | 11 | 1 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Products under Development by Indication | 12 | 2 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Unknown Stage Products | 16 | 1 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Products under Development by Companies | 17 | 4 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Products under Development by Universities/Institutes | 21 | 2 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Therapeutics Assessment | 23 | 4 |
| Assessment by Monotherapy/Combination Products | 23 | 1 |
| Assessment by Mechanism of Action | 24 | 1 |
| Assessment by Route of Administration | 25 | 1 |
| Assessment by Molecule Type | 26 | 1 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Companies Involved in Therapeutics Development | 27 | 10 |
| Adamed Sp. z o.o. | 27 | 1 |
| Avineuro Pharmaceuticals, Inc. | 28 | 1 |
| Axovant Sciences Ltd. | 29 | 1 |
| Biotie Therapies Corp. | 30 | 1 |
| Celon Pharma Sp. z o.o. | 31 | 1 |
| Galenea Corp. | 32 | 1 |
| H. Lundbeck A/S | 33 | 1 |
| Reviva Pharmaceuticals Inc. | 34 | 1 |
| Suven Life Sciences Ltd. | 35 | 1 |
| Teva Pharmaceutical Industries Ltd. | 36 | 1 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Drug Profiles | 37 | 33 |
| ADN-1184 Drug Profile | 37 | 1 |
| ADN-2013 Drug Profile | 38 | 1 |
| ADN-3662 Drug Profile | 39 | 1 |
| AV-3208 Drug Profile | 40 | 1 |
| AVN-0189 Drug Profile | 41 | 1 |
| AVN-101 Drug Profile | 42 | 1 |
| AVN-211 Drug Profile | 43 | 1 |
| AVN-3085 Drug Profile | 44 | 1 |
| AVN-3205 Drug Profile | 45 | 1 |
| AVN-322 Drug Profile | 46 | 1 |
| idalopirdine Drug Profile | 47 | 2 |
| intepirdine Drug Profile | 49 | 2 |
| landipirdine Drug Profile | 51 | 2 |
| LuAF-35700 Drug Profile | 53 | 1 |
| RP-5063 Drug Profile | 54 | 2 |
| Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders Drug Profile | 56 | 1 |
| Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders Drug Profile | 57 | 1 |
| Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia Drug Profile | 58 | 1 |
| Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease Drug Profile | 59 | 1 |
| Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders Drug Profile | 60 | 1 |
| Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment Drug Profile | 61 | 1 |
| Small Molecules to Target 5-HT2C and 5-HT6 Receptor for Schizophrenia Drug Profile | 62 | 2 |
| SUVN-501 Drug Profile | 64 | 2 |
| SUVN-502 Drug Profile | 66 | 2 |
| SUVN-507 Drug Profile | 68 | 1 |
| SUVN-512 Drug Profile | 69 | 1 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Dormant Projects | 70 | 5 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Discontinued Products | 75 | 1 |
| 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Featured News &Press Releases | 76 | 10 |
| Jul 07, 2016: Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA) | 76 | 1 |
| May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016 | 76 | 1 |
| Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia | 77 | 1 |
| Apr 11, 2016: Lundbeck to Present Data on Idalopirdine at American Academy of Neurology | 78 | 1 |
| Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia | 78 | 1 |
| Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia | 79 | 1 |
| Dec 07, 2015: Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer s Disease | 80 | 1 |
| Oct 28, 2015: Axovant Sciences Announces RVT-101 Presentations At The Clinical Trials In Alzheimer's Disease Meeting | 81 | 1 |
| Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits | 81 | 1 |
| Oct 06, 2015: Axovant Sciences Announces Start Of Confirmatory Phase 3 MINDSET Study And Special Protocol Assessment Agreement With FDA | 82 | 1 |
| Jul 22, 2015: Axovant's RVT-101 Phase 2b Completer Analysis Demonstrates Statistically Significant Benefits in Cognition and Function Through 48 Weeks | 82 | 2 |
| Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist | 84 | 1 |
| Jun 29, 2015: Axovant Sciences To Present RVT-101 Alzheimer's Disease Clinical Data At AAIC 2015 Meeting | 84 | 1 |
| Dec 23, 2014: Biotie Announces Start Of Syn120 Phase 2A Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events | 85 | 1 |
| Sep 08, 2014: Suven Life Sciences Provides Update On Its Molecule For Alzheimer's Disease | 85 | 1 |
| Appendix | 86 | 2 |
| Methodology | 86 | 1 |
| Coverage | 86 | 1 |
| Secondary Research | 86 | 1 |
| Primary Research | 86 | 1 |
| Expert Panel Validation | 86 | 1 |
| Contact Us | 86 | 1 |
| Disclaimer | 87 | 1 |
